Durvalumab with Chemotherapy as First Line Treatment in Patients with Advanced Biliary Tract Cancers (aBTCs)

Trial Identifier: D4191C00140
Sponsor: AstraZeneca
Start Date: August 2023
Primary Completion Date: September 2025
Study Completion Date: March 2026
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
DE Chemnitz, DE, 09131
DE Hannover, DE, 30625
ES Barcelona, ES, 08035
ES Madrid, ES, 28041
ES Madrid, ES, 28040
ES Madrid, ES, 28027
ES Pamplona, ES, 31008
ES Sevilla, ES, 41013
FR Clichy, FR, 92110
FR DIJON, FR, 21079
FR Montpellier Cedex 5, FR, 34090
FR Villejuif, FR, 94800
IT Castelfranco Veneto, IT, 31033
IT Foggia, IT, 71122
IT Palermo, IT, 90146
IT Pisa, IT, 56126
IT Rozzano, IT, 20089
JP Chuo-ku, JP, 104-0045
JP Kanazawa-shi, JP, 920-8641
JP Kashiwa, JP, 227-8577
JP Kyoto, JP, 606-8507
JP Osaka, JP, 541-8567
JP Sendai, JP, 980-8574
JP Ube, JP, 755-8505
JP wakayama, JP, 641-8509
JP Yokohama, JP, 241-8515
KR Seoul, KR, 03080
KR Seoul, KR, 05505
KR Seoul, KR, 06351
SG Singapore, SG, 169610
US, Alabama Mobile, Alabama, US, 36607
US, CA Orange, CA, US, 92868
US, DC Washington, DC, US, 20007
US, OR Portland, OR, US, 97213